Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth

Giovanni Grasso, Virginia Rodriguez-Menendez, Giulia De Michele, Giuseppe Piedemonte, Sara Martone, Pietro Ghezzi, Giuseppe Lauria, Alessandra Sfacteria, Patrizia Beccaglia, Norberto Oggioni, Guido Cavaletti, Tina Colombo, Maurizio D'Incalci, Roberto Bianchi, Alessandra Gilardini, Annalisa Canta

Risultato della ricerca: Articlepeer review

54 Citazioni (Scopus)

Abstract

This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.
Lingua originaleEnglish
pagine (da-a)710-717
Numero di pagine8
RivistaEuropean Journal of Cancer
Volume43
Stato di pubblicazionePublished - 2007

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth'. Insieme formano una fingerprint unica.

Cita questo